Analyst firms · Morgan Stanley · BNTX
Morgan Stanley BNTX price target and rating history
BioNTech SE (BNTX) · Health Care
Morgan Stanley rates BioNTech SE (BNTX) Overweight with a $145 price target, as of its latest action on Sep 24, 2024. It has published 4 rating actions on BNTX since December 2021, including 1 upgrade and 0 downgrades. Across 5 firms with a BNTX price target in the last 12 months, the median target is $113.
- Current rating
- Overweight
- Price target
- $145
- Median target, all firms
- $113
- Actions on BNTX
- 4
Morgan Stanley price target on BNTX
Every Morgan Stanley rating on BNTX
- Sep 24, 2024
- Feb 1, 2022
- Jan 18, 2022
- Dec 16, 2021
How other firms rate BNTX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Argus Research | Hold | Oct 8, 2026 | |
| BMO Capital Markets | Market Perform | $105 | Sep 8, 2026 |
| UBS | Buy | $135 | May 27, 2026 |
| Bernstein | Mkt Perform | $96 | May 22, 2026 |
| Leerink Partners | Market Perform | $113 | Feb 2, 2026 |
| Goldman Sachs | Buy | $142 | Jan 16, 2026 |
Questions about Morgan Stanley and BNTX
- What is Morgan Stanley's price target for BNTX?
- Morgan Stanley's latest stated price target for BioNTech SE (BNTX) is $145, from its action on Sep 24, 2024.
- What is Morgan Stanley's rating on BNTX?
- Morgan Stanley rates BNTX Overweight, a bullish rating, as of Sep 24, 2024.
- When did Morgan Stanley last change its view on BNTX?
- On Sep 24, 2024, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $93 to $145.
- How does Morgan Stanley's BNTX target compare with other analysts?
- Across 5 firms with a BNTX price target in the last 12 months, the median target is $113.
More BNTX rating histories
All Morgan Stanley ratingsBNTX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.